M&A / Deals Biogen uplifts rare disease pipeline with $5.6bn Apellis buyout Pharmaceutical TechnologyBiogen's acquisition of Apellis Pharmaceuticals will add Syfovre and Empaveli to the latter company's portfolio of medicines.M&A / DealsRare DiseaseRead full story pharminent April 1, 2026 (Last updated: April 1, 2026) Pharmaceutical Technology Biogen’s acquisition of Apellis Pharmaceuticals will add Syfovre and Empaveli to the latter company’s portfolio of medicines. M&A / DealsRare DiseaseRead full story Post navigation Previous: Telomir seeks FDA approval for Telomir-1 to treat breast cancerNext: Agios mulls early FDA filing for sickle cell therapy Related Stories M&A / Deals Assertio accepts new buyout bid; AI biotech Isomorphic banks $2B pharminent May 13, 2026 M&A / Deals BMS, Hengrui build 13-asset pipeline in $15B+ onco-immune deal pharminent May 12, 2026 M&A / Deals Cellular Intelligence scoops up Novo’s Parkinson’s therapy pharminent May 12, 2026
